Subcutaneous Secukinumab Relieves Psoriatic Arthritis

The interleukin-17A inhibitor is effective and safe, according to first results from the ongoing FUTURE5 study, the largest controlled trial of a biologic for psoriatic arthritis to date.
Medscape Medical News

http://ift.tt/2ihnOzz